_256_384.jpg)
News | March 01, 2024
Suven announces merger of Cohance Lifesciences
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
The objective of GCMC is well aligned to WHO’s call to action and India’s National Biotechnology Development Strategy
The board gave in-principle approval for expansion of company's footprint in Lucknow
The observations do not pose any risk to site's compliance standards or its business continuity
Leishmaniasis is caused by protozoan parasites which are transmitted by the bite of infected female phlebotomine sandflies
Suven Pharmaceuticals’ API and forumulations facilities complete USFDA inspection successfully
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
AIIMS Rewari is a 750-bed hospital complex which includes a 100 seat medical college, a 60 seat nursing college, a 30-bed AYUSH block
It is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation
Subscribe To Our Newsletter & Stay Updated
